HC Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals
HC Wainwright maintains its buy rating for Ionis Pharmaceuticals with a $130 price target, a 60.14% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating on Ionis Pharmaceuticals, setting a price target of $130 as of June 25, 2026.
- HC Wainwright's $130 price target implies 60.14% upside from Ionis Pharmaceuticals, Inc.'s ($IONS) current $81.18 share price.
- Shares of Ionis Pharmaceuticals traded near $76.52 on Thursday with a market cap of approximately $12.54 billion.
- Ionis Pharmaceuticals is a biotech company focused on RNA-targeted medicines, headquartered in Carlsbad, CA.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its buy rating on Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS), maintaining a price target of $130. The announcement came on June 25, 2026, with shares trading around $76.52 on that Thursday.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Analysts Set New Price Targets
On June 25, 2026, HC Wainwright & Co. maintained its buy rating on Ionis Pharmaceuticals with a price target of $130. Earlier, on June 17, Leerink Partners also maintained a buy rating, setting a target of $122. Citigroup initiated coverage with a buy rating and a $115 target on May 19, 2026. RBC Capital and Barclays both maintained buy ratings on April 30, 2026, with targets of $100 and $115, respectively.
Ionis Pharmaceuticals, Inc. Stock Up 33.0%
Shares of Ionis Pharmaceuticals, listed on the NasdaqGS under the ticker IONS, traded near $76.52 on Thursday. The company has a market cap of about $12.54 billion. Although it is not currently profitable, the forward P/E ratio is -102.0, reflecting anticipated future earnings. The stock's beta is 0.37, indicating lower volatility compared to the market. Over the past year, Ionis shares have ranged from a low of $36.93 to a high of $86.74, with a 50-day moving average of $74.90 and a 200-day moving average of $75.00. The company maintains a strong current ratio of 4.10, though its debt-to-equity ratio is high at 531.05.
$IONS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Ionis Pharmaceuticals, Inc.
Insider activity at Ionis Pharmaceuticals included transactions by Spencer Berthelsen, who bought and sold 8,000 shares on June 15, 2026. The shares were bought at an average price of $24.42 and sold under a planned transaction at $73.49. Holly Kordasiewicz, EVP and Chief Development Officer, sold 60,846 shares on June 12, 2026, at an average price of $73.40 under a planned sale.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California. It specializes in developing RNA-targeted medicines for a variety of diseases. The company offers treatments for conditions such as familial chylomicronemia syndrome, hereditary angioedema, and spinal muscular atrophy. Ionis also collaborates with major pharmaceutical companies like Biogen and AstraZeneca to advance its drug pipeline. Led by CEO Dr. Brett P. Monia, the company employs over 1,400 people and continues to focus on innovative therapies.
Bottom Line
HC Wainwright's reaffirmation of its buy rating for Ionis Pharmaceuticals highlights positive sentiment among analysts, with a strong price target of $130. Investors watch these ratings closely as they provide insights into potential future performance. However, it's important to note that these ratings reflect analysts' views at the time and may change as new information becomes available.
Get Ionis Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IONS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.